Interações de Memantina + donepezila

Pyridostigmine bromide extended-release tablets are contraindicated in patients with: Mechanical intestinal or urinary obstruction Known hypersensitivity to pyridostigmine or other anticholinesterase agents Mechanical intestinal or urinary obstruction. (bula de Piridostigmina, Contraindicações)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Use of Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Peptic Ulcer Disease and Gastrointestinal Bleeding Through their primary action, cholinesterase inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Use of Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Use of Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Peptic Ulcer Disease and Gastrointestinal Bleeding Through their primary action, cholinesterase inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Cholinesterase inhibitors: Concomitant administration may increase the risk of cocaine toxicity. (bula de Cocaína, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Use of Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. (bula de Memantina + donepezila, Interações medicamentosas)

Use of Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. (bula de Memantina + donepezila, Interações medicamentosas)

Dicyclomine hydrochloride should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase (5.4) (bula de Dicicloverina, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Peptic Ulcer Disease and Gastrointestinal Bleeding Through their primary action, cholinesterase inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium. (bula de Esmolol, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

In case of simultaneous administration of other cholinesterase inhibitors (e.g. medicines for the treatment of dementia), caution should be exercised because of the potentiating effect. (bula de Fisostigmina, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Use with caution due to aggravation of symptoms: Pre-existing dementia in patients treated with cholinesterase inhibitors ( 5.2 ), Parkinson’s disease ( 5.2 ), Myasthenia gravis ( 5.3 ), and Decreased gastrointestinal motility in patients with autonomic neuropathy ( 5.4 ). (bula de Oxibutinina, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Peptic Ulcer Disease and Gastrointestinal Bleeding Through their primary action, cholinesterase inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Myasthenia Gravis Patients with myasthenia gravis may show worsening of symptoms from PA due to its procaine-like effect on diminishing acetylcholine release at skeletal muscle motor nerve endings, so that PA administration may be hazardous without optimal adjustment of anticholinesterase medications and other precautions. (bula de Procainamida, Advertências)

Use of Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. (bula de Memantina + donepezila, Interações medicamentosas)

Donepezil: Increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is coadministered with donepezil. (bula de Ramelteona, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

NAMZARIC is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia. (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (bula de Memantina + donepezila, Advertências e precauções)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. (bula de Dipiridamol, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Use of Donepezil with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors, including donepezil hydrochloride, are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Anticholinesterases : Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Metilprednisolona, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Use of Donepezil with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors, including donepezil hydrochloride, are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Prednisolona, Interações medicamentosas)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Prednisona, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Use of Donepezil with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors, including donepezil hydrochloride, are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol. (bula de Memantina + donepezila, Interações medicamentosas)

Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. (bula de Memantina + donepezila, Interações medicamentosas)

Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. (bula de Memantina + donepezila, Interações medicamentosas)

Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. (bula de Memantina + donepezila, Interações medicamentosas)

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (bula de Triancinolona, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

NAMZARIC may interfere with anticholinergic medications. (bula de Memantina + donepezila, Interações medicamentosas)

Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (bula de Memantina + donepezila, Interações medicamentosas)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (bula de Memantina + donepezila, Interações medicamentosas)

In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (bula de Risperidona, Interações medicamentosas)